Chengdu Easton Biopharmaceuticals Co Ltd
Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms comprising capsules, tablets, and injections, as well as active pharmaceutical ingredients (API). It also offers API products, such as Apixaban for cardiovascular applications; A… Read more
Chengdu Easton Biopharmaceuticals Co Ltd (688513) - Total Assets
Latest total assets as of September 2025: CN¥3.56 Billion CNY
Based on the latest financial reports, Chengdu Easton Biopharmaceuticals Co Ltd (688513) holds total assets worth CN¥3.56 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Chengdu Easton Biopharmaceuticals Co Ltd - Total Assets Trend (2013–2024)
This chart illustrates how Chengdu Easton Biopharmaceuticals Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Chengdu Easton Biopharmaceuticals Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Chengdu Easton Biopharmaceuticals Co Ltd's total assets of CN¥3.56 Billion consist of 56.7% current assets and 43.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 28.6% |
| Accounts Receivable | CN¥288.88 Million | 8.5% |
| Inventory | CN¥190.09 Million | 5.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥109.37 Million | 3.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Chengdu Easton Biopharmaceuticals Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chengdu Easton Biopharmaceuticals Co Ltd's current assets represent 56.7% of total assets in 2024, an increase from 34.8% in 2013.
- Cash Position: Cash and equivalents constituted 28.6% of total assets in 2024, up from 11.3% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 5.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 8.5% of total assets.
Chengdu Easton Biopharmaceuticals Co Ltd Competitors by Total Assets
Key competitors of Chengdu Easton Biopharmaceuticals Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Chengdu Easton Biopharmaceuticals Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Chengdu Easton Biopharmaceuticals Co Ltd generates 0.40x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Chengdu Easton Biopharmaceuticals Co Ltd generates $7.01 in net profit.
Chengdu Easton Biopharmaceuticals Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.50 | 2.93 | 4.92 |
| Quick Ratio | 3.12 | 2.65 | 4.70 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.48 Billion | CN¥ 1.28 Billion | CN¥ 1.51 Billion |
Chengdu Easton Biopharmaceuticals Co Ltd - Advanced Valuation Insights
This section examines the relationship between Chengdu Easton Biopharmaceuticals Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.97 |
| Latest Market Cap to Assets Ratio | 0.18 |
| Asset Growth Rate (YoY) | 1.6% |
| Total Assets | CN¥3.40 Billion |
| Market Capitalization | $623.86 Million USD |
Valuation Analysis
Below Book Valuation: The market values Chengdu Easton Biopharmaceuticals Co Ltd's assets below their book value (0.18 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Chengdu Easton Biopharmaceuticals Co Ltd's assets grew by 1.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Chengdu Easton Biopharmaceuticals Co Ltd (2013–2024)
The table below shows the annual total assets of Chengdu Easton Biopharmaceuticals Co Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.40 Billion | +1.59% |
| 2023-12-31 | CN¥3.35 Billion | +10.91% |
| 2022-12-31 | CN¥3.02 Billion | +8.73% |
| 2021-12-31 | CN¥2.78 Billion | +9.66% |
| 2020-12-31 | CN¥2.53 Billion | +156.40% |
| 2019-12-31 | CN¥987.08 Million | +25.00% |
| 2018-12-31 | CN¥789.69 Million | +33.40% |
| 2017-12-31 | CN¥591.98 Million | +13.79% |
| 2016-12-31 | CN¥520.22 Million | +66.94% |
| 2015-12-31 | CN¥311.63 Million | +10.08% |
| 2014-12-31 | CN¥283.10 Million | +11.08% |
| 2013-12-31 | CN¥254.86 Million | -- |